Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

332 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Picoliter-Droplet Digital Polymerase Chain Reaction-Based Analysis of Cell-Free Plasma DNA to Assess EGFR Mutations in Lung Adenocarcinoma That Confer Resistance to Tyrosine-Kinase Inhibitors.
Seki Y, Fujiwara Y, Kohno T, Takai E, Sunami K, Goto Y, Horinouchi H, Kanda S, Nokihara H, Watanabe S, Ichikawa H, Yamamoto N, Kuwano K, Ohe Y. Seki Y, et al. Among authors: sunami k. Oncologist. 2016 Feb;21(2):156-64. doi: 10.1634/theoncologist.2015-0288. Epub 2016 Jan 14. Oncologist. 2016. PMID: 26768482 Free PMC article.
Phase II study of oral vitamin B12 supplementation as an alternative to intramuscular injection for patients with non-small cell lung cancer undergoing pemetrexed therapy.
Takagi Y, Hosomi Y, Nagamata M, Watanabe K, Takahashi S, Nakahara Y, Yomota M, Sunami K, Okuma Y, Shimokawa T, Okamura T. Takagi Y, et al. Among authors: sunami k. Cancer Chemother Pharmacol. 2016 Mar;77(3):559-64. doi: 10.1007/s00280-015-2954-x. Epub 2016 Jan 28. Cancer Chemother Pharmacol. 2016. PMID: 26821156 Clinical Trial.
Phase II trial of S-1 treatment as palliative-intent chemotherapy for previously treated advanced thymic carcinoma.
Okuma Y, Goto Y, Ohyanagi F, Sunami K, Nakahara Y, Kitazono S, Kudo K, Tambo Y, Kanda S, Yanagitani N, Horiike A, Horinouchi H, Fujiwara Y, Nokihara H, Yamamoto N, Nishio M, Ohe Y, Hosomi Y. Okuma Y, et al. Among authors: sunami k. Cancer Med. 2020 Oct;9(20):7418-7427. doi: 10.1002/cam4.3385. Epub 2020 Aug 19. Cancer Med. 2020. PMID: 32813912 Free PMC article. Clinical Trial.
Comparison of the pharmacokinetics of erlotinib administered in complete fasting and 2 h after a meal in patients with lung cancer.
Katsuya Y, Fujiwara Y, Sunami K, Utsumi H, Goto Y, Kanda S, Horinouchi H, Nokihara H, Yamamoto N, Takashima Y, Osawa S, Ohe Y, Tamura T, Hamada A. Katsuya Y, et al. Among authors: sunami k. Cancer Chemother Pharmacol. 2015 Jul;76(1):125-32. doi: 10.1007/s00280-015-2778-8. Epub 2015 May 21. Cancer Chemother Pharmacol. 2015. PMID: 25994853 Clinical Trial.
Study protocol for NCCH1908 (UPFRONT-trial): a prospective clinical trial to evaluate the feasibility and utility of comprehensive genomic profiling prior to the initial systemic treatment in advanced solid tumour patients.
Mizuno T, Yoshida T, Sunami K, Koyama T, Okita N, Kubo T, Sudo K, Shimoi T, Ueno H, Saito E, Katanoda K, Shibata T, Yonemori K, Okusaka T, Boku N, Ohe Y, Hiroshima Y, Ueno M, Kuboki Y, Doi T, Nakamura K, Kohno T, Yatabe Y, Yamamoto N. Mizuno T, et al. Among authors: sunami k. Jpn J Clin Oncol. 2021 Dec 1;51(12):1757-1760. doi: 10.1093/jjco/hyab159. Jpn J Clin Oncol. 2021. PMID: 34622931
A Learning Program for Treatment Recommendations by Molecular Tumor Boards and Artificial Intelligence.
Sunami K, Naito Y, Saigusa Y, Amano T, Ennishi D, Imai M, Kage H, Kanai M, Kenmotsu H, Komine K, Koyama T, Maeda T, Morita S, Sakai D, Hirata M, Ito M, Kozuki T, Sakashita H, Horinouchi H, Okuma Y, Takashima A, Kubo T, Hironaka S, Segawa Y, Yakushijin Y, Bando H, Makiyama A, Suzuki T, Kinoshita I, Kohsaka S, Ohe Y, Ishioka C, Yamamoto K, Tsuchihara K, Yoshino T. Sunami K, et al. JAMA Oncol. 2024 Jan 1;10(1):95-102. doi: 10.1001/jamaoncol.2023.5120. JAMA Oncol. 2024. PMID: 38032680 Free PMC article.
332 results